A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers
- 30 January 2024
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (4) , 1142-1151
Abstract
Aims: Shiga toxin‐producing Escherichia coli‐haemolytic uraemic syndrome (STEC‐HUS) is considered a toxaemic disorder in which early intervention with neutralizing antibodies may have therapeutic benefits. INM004, composed of F (ab′)2 fragments from equine immunoglobulins, neutralizes Stx1/Stx2, potentially preventing the onset of HUS.Methods: A single‐centre, randomized, phase 1, single‐blind, placebo‐controlled clinical trial to evaluate INM004 safety, tolerance and pharmacokinetics (PK) in healthy adult volunteers, was conducted; in stage I, eight subjects were divided in two cohorts (n = 4) to receive a single INM004 dose of 2 or 4 mg kg−1, or placebo (INM004:placebo ratio of 3:1). In stage II, six subjects received three INM004 doses of 4 mg kg−1 repeated every 24 h, or placebo (INM004:placebo ratio of 5:1).Results: Eight subjects (57.1%) experienced mild treatment‐emergent adverse events (TEAEs); most frequent were rhinitis, headache and flushing, resolved within 24 h without changes in treatment or additional intervention. No serious AEs were reported. Peak concentrations of INM004 occurred within 2 h after infusion, with median Cmax values of 45.1 and 77.7 μg mL−1 for 2 and 4 mg kg−1, respectively. The serum concentration of INM004 declined in a biphasic manner (t1/2 range 30.7–52.9 h). Systemic exposures increased with each subsequent dose in a dose‐proportional manner, exhibiting accumulation. Geometric median Cmax and AUC values were 149 and 10 300 μg h mL−1, respectively, in the repeated dose regimen. Additionally, samples from subjects that received INM004 at 2 mg kg−1 showed neutralizing capacity against Stx1 and Stx2 in in vitro assays.Conclusions: The results obtained in this first‐in‐human study support progression into the phase 2 trial in children with HUS.Keywords
All Related Versions
This publication has 12 references indexed in Scilit:
- RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trialeClinicalMedicine, 2021
- Two decades of pharmacovigilance and clinical experience with highly purified rabies immunoglobulin F(ab')2 fragmentsExpert Review of Vaccines, 2016
- Serum Shiga toxin 2 values in patients during acute phase of diarrhoea‐associated haemolytic uraemic syndromeActa Paediatrica, 2015
- Safety of intravenous equine F(ab')2: Insights following clinical trials involving 1534 recipients of scorpion antivenomToxicon, 2013
- Immunization with a Chimera Consisting of the B Subunit of Shiga Toxin Type 2 and Brucella Lumazine Synthase Confers Total Protection against Shiga Toxins in MiceThe Journal of Immunology, 2013
- An Epidemiologic Surveillance of Shiga-like Toxin-producing Escherichia coli Infection in Argentinean ChildrenThe Pediatric Infectious Disease Journal, 2012
- Clinical Relevance of Shiga Toxin Concentrations in the Blood of Patients With Hemolytic Uremic SyndromeThe Pediatric Infectious Disease Journal, 2011
- Rabies Post-Exposure Prophylaxis in the Philippines: Health Status of Patients Having Received Purified Equine F(ab')2 Fragment Rabies Immunoglobulin (Favirab)PLOS Neglected Tropical Diseases, 2008
- Clinical safety of a polyvalent F(ab′)2 equine antivenom in 223 African snake envenomations: a field trial in CameroonTransactions of the Royal Society of Tropical Medicine and Hygiene, 1998
- The Hemolytic-Uremic SyndromeNephron, 1973